Cargando…

Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine

Despite the revolutionary progress of immune checkpoint inhibitors (CPIs) for cancer immunotherapy, CPIs are effective only in a subset of patients. Combining CPIs and cancer vaccines to achieve better clinical outcomes is a reasonable approach since CPI enhances cancer vaccine-induced tumor-associa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shirakawa, Toshiro, Kitagawa, Koichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2017
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791589/ https://www.ncbi.nlm.nih.gov/pubmed/29048978 http://dx.doi.org/10.1080/21645515.2017.1382787

Ejemplares similares

An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia
por: Nakagawa, Natsuki, et al.
Publicado: (2022)

Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide
por: Oji, Yusuke, et al.
Publicado: (2016)

Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia
por: Minagawa, Hikaru, et al.
Publicado: (2023)

Long term efficacy of WT1 peptide vaccine in patients with WT1 overexpressing hematopoeitic and solid malignancies
por: Letsch, Anne, et al.
Publicado: (2013)

Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome
por: Ueda, Yasunori, et al.
Publicado: (2017)

WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1
por: Oji, Yusuke, et al.
Publicado: (2023)

WT1 peptide analogue WT1-126Y enhances leukemia lysis
por: Alqudaihi, Ghofran, et al.
Publicado: (2014)

Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides
por: Nakata, Jun, et al.
Publicado: (2018)

WT1 peptide-based immunotherapy for refractory thymic epithelial malignancies
por: Suzuki, Mikito, et al.
Publicado: (2019)

Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination
por: Busse, Antonia, et al.
Publicado: (2010)

Wilms’ Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses
por: Uttenthal, Benjamin, et al.
Publicado: (2014)

WT1 Peptide Cancer Vaccine for Patients with Hematopoietic Malignancies and Solid Cancers
por: Oka, Yoshihiro, et al.
Publicado: (2007)

Wt1, the mesothelium and the origins and heterogeneity of visceral fat progenitors
por: Chau, You-Ying, et al.
Publicado: (2015)

WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia
por: Liu, Hongtao, et al.
Publicado: (2018)

WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine
por: Alzaaqi, Shouq, et al.
Publicado: (2022)

Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission
por: Manning-Geist, Beryl L., et al.
Publicado: (2023)

WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML IN THE CHRONIC PHASE
por: Narita, Miwako, et al.
Publicado: (2010)

WT1-AS promotes cell apoptosis in hepatocellular carcinoma through down-regulating of WT1
por: Lv, Long, et al.
Publicado: (2015)

Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer
por: Nishida, Sumiyuki, et al.
Publicado: (2014)

Development of cellular and humoral response against WT1 protein vaccination in mice
por: Nicoli, Paolo, et al.
Publicado: (2015)

An oral cancer vaccine using a Bifidobacterium vector suppresses tumor growth in a syngeneic mouse bladder cancer model
por: Kitagawa, Koichi, et al.
Publicado: (2021)

Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine
por: Takashima, Satoshi, et al.
Publicado: (2016)

Enhanced immune reaction resulting from co-vaccination of WT1 helper peptide assessed on PET-CT
por: Nakata, Jun, et al.
Publicado: (2020)

Editorial: WT1 in Development and Disease
por: Chau, You-Ying, et al.
Publicado: (2022)

Microstructure and Hot Deformation Behavior of the Mg–8 wt.% Sn–1.5 wt.% Al Alloy
por: Sun, Zhaoqian, et al.
Publicado: (2021)

Role for first zinc finger of WT1 in DNA sequence specificity: Denys–Drash syndrome-associated WT1 mutant in ZF1 enhances affinity for a subset of WT1 binding sites
por: Wang, Dongxue, et al.
Publicado: (2018)

Co-Precipitation, Strength and Electrical Resistivity of Cu–26 wt % Ag–0.1 wt % Fe Alloy
por: Li, Rui, et al.
Publicado: (2017)

An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model
por: Ueki, Hideto, et al.
Publicado: (2023)

The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST)
por: Nannini, Margherita, et al.
Publicado: (2017)

WT1 regulates angiogenesis in Ewing Sarcoma
por: Katuri, Varalakshmi, et al.
Publicado: (2014)

Genomic Organization of the Human WT1 Gene
por: Tadokoro, Keiko, et al.
Publicado: (1992)

Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide
por: Naoe, Tomoki, et al.
Publicado: (2023)

Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms
por: Tatsumi, Naoya, et al.
Publicado: (2015)

WT1 Gene Mutations, rs16754 Variant, and WT1 Overexpression as Prognostic Factors in Acute Myeloid Leukemia Patients
por: Koczkodaj, Dorota, et al.
Publicado: (2022)

A WT1-positive pleural neoplasm. Is it always a mesothelioma?: Diagnostic pitfall of WT1 immunohistochemistry in pleural neoplasm
por: Gaggero, G, et al.
Publicado: (2023)

Human CLEC9A antibodies deliver Wilms' tumor 1 (WT1) antigen to CD141(+) dendritic cells to activate naïve and memory WT1‐specific CD8(+) T cells
por: Pearson, Frances E, et al.
Publicado: (2020)

Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909
por: Kuball, Jürgen, et al.
Publicado: (2010)

An overlooked subset of Cx3cr1(wt/wt) microglia in the Cx3cr1(CreER-Eyfp/wt) mouse has a repopulation advantage over Cx3cr1(CreER-Eyfp/wt) microglia following microglial depletion
por: Zhou, Kai, et al.
Publicado: (2022)

Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies
por: Di Stasi, Antonio, et al.
Publicado: (2015)

A high incidence of WT1 abnormality in bilateral Wilms tumours in Japan, and the penetrance rates in children with WT1 germline mutation
por: Kaneko, Y, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_f8qqpj5t1rvuc303ai81aegvpq